JP2008508886A5 - - Google Patents

Download PDF

Info

Publication number
JP2008508886A5
JP2008508886A5 JP2007525034A JP2007525034A JP2008508886A5 JP 2008508886 A5 JP2008508886 A5 JP 2008508886A5 JP 2007525034 A JP2007525034 A JP 2007525034A JP 2007525034 A JP2007525034 A JP 2007525034A JP 2008508886 A5 JP2008508886 A5 JP 2008508886A5
Authority
JP
Japan
Prior art keywords
seq
reading frame
open reading
active bont
molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007525034A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008508886A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/027917 external-priority patent/WO2006017749A2/en
Publication of JP2008508886A publication Critical patent/JP2008508886A/ja
Publication of JP2008508886A5 publication Critical patent/JP2008508886A5/ja
Pending legal-status Critical Current

Links

JP2007525034A 2004-08-04 2005-08-03 活性ボツリヌス毒素ａ型の発現の最適化 Pending JP2008508886A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US59912104P 2004-08-04 2004-08-04
PCT/US2005/027917 WO2006017749A2 (en) 2004-08-04 2005-08-03 Optimizing expression of active botulinum toxin type a

Publications (2)

Publication Number Publication Date
JP2008508886A JP2008508886A (ja) 2008-03-27
JP2008508886A5 true JP2008508886A5 (cg-RX-API-DMAC7.html) 2008-09-18

Family

ID=35355531

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007525034A Pending JP2008508886A (ja) 2004-08-04 2005-08-03 活性ボツリヌス毒素ａ型の発現の最適化

Country Status (6)

Country Link
US (2) US20080057575A1 (cg-RX-API-DMAC7.html)
EP (1) EP1773874B1 (cg-RX-API-DMAC7.html)
JP (1) JP2008508886A (cg-RX-API-DMAC7.html)
AU (1) AU2005271372B2 (cg-RX-API-DMAC7.html)
CA (1) CA2575994A1 (cg-RX-API-DMAC7.html)
WO (1) WO2006017749A2 (cg-RX-API-DMAC7.html)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7514088B2 (en) 2005-03-15 2009-04-07 Allergan, Inc. Multivalent Clostridial toxin derivatives and methods of their use
US20080057575A1 (en) * 2004-08-04 2008-03-06 Allergan, Inc. Optimizing Expression of Active Botulinum Toxin Type A
WO2006068794A2 (en) 2004-11-22 2006-06-29 New York University Genetically engineered clostridial genes, proteins encoded by the engineered genes, and uses thereof
ATE518882T1 (de) 2005-09-19 2011-08-15 Allergan Inc Mit clostridientoxin aktivierbare clostridientoxine
US8168206B1 (en) 2005-10-06 2012-05-01 Allergan, Inc. Animal protein-free pharmaceutical compositions
EP2021489A2 (en) * 2006-05-30 2009-02-11 Dow Global Technologies Inc. Codon optimization method
CA2693958A1 (en) 2007-06-14 2008-12-18 Emergent Biosolutions, Inc. Chemically modified peptides with improved immunogenicity
CN105833254A (zh) 2008-12-10 2016-08-10 阿勒根公司 梭菌毒素药物组合物
EP2218783A1 (en) 2009-02-05 2010-08-18 Merz Pharma GmbH & Co. KGaA Novel method for the manufacturing of neurotoxins
KR101923847B1 (ko) 2009-03-13 2018-11-29 알러간, 인코포레이티드 면역 기반 재표적화된 엔도펩티다제 활성 검정
SG181772A1 (en) 2009-12-16 2012-07-30 Allergan Inc Modified clostridial toxins comprising an integrated protease cleavage site-binding domain
EP2528941A4 (en) * 2010-01-25 2013-05-29 Univ New York FOR TRANSPORT STUDIES AND NEURONAL ADMINISTRATION, MANIPULATED RECOMBINANT DERIVATIVES FROM BOTULINUM NEUROTOXINES
JP5956350B2 (ja) 2010-01-25 2016-07-27 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 単鎖タンパク質をそれらの２鎖形態に細胞内変換する方法
MX2013005749A (es) 2010-11-23 2013-08-01 Allergan Inc Composiciones y metodos para producir enterocinasa en levaduras.
US20120244188A1 (en) 2011-03-25 2012-09-27 Allergan, Inc. Treatment of Sensory Disturbance Disorders
US20120251573A1 (en) 2011-03-28 2012-10-04 Allergan, Inc. Endopeptidase Treatment of Neuroendocrine Disorders
US20120251575A1 (en) 2011-03-28 2012-10-04 Allergan, Inc. Endopeptidase Treatment of Involuntary Movement Disorders
US20120251574A1 (en) 2011-03-28 2012-10-04 Allergan, Inc. Endopeptidase and Neurotoxin Combination Treatment of Multiple Medical Conditions
US20120251515A1 (en) 2011-03-29 2012-10-04 Allergan, Inc. Endopeptidase Treatment of Cosmesis Disorders
US20120251518A1 (en) 2011-03-29 2012-10-04 Allergan, Inc. Endopeptidase Treatment of Sexual Dysfunction Disorders
US20120251519A1 (en) 2011-03-29 2012-10-04 Allergan, Inc. Endopeptidase Treatment of Smooth Muscle Disorders
WO2012135304A1 (en) 2011-03-29 2012-10-04 Allergan, Inc. Vagal nerve-based disorders
EP2709723B1 (en) * 2011-05-17 2019-11-20 Boston Scientific Neuromodulation Corporation User-defined graphical shapes used as a visualization aid for stimulator programming
WO2012174123A1 (en) 2011-06-13 2012-12-20 Allergan, Inc. Treatment of psychological trauma
EP2793934B1 (en) 2011-12-23 2017-08-23 Merz Pharma GmbH & Co. KGaA Novel method for the manufacturing of di-chain proteins for use in humans
US20130171122A1 (en) 2011-12-29 2013-07-04 Allergan, Inc. Endopeptidase and neurotoxin combination treatment of bladder disorders
WO2014079495A1 (en) * 2012-11-21 2014-05-30 Syntaxin Limited Methods for the manufacture of proteolytically processed polypeptides
US9315549B2 (en) 2013-01-28 2016-04-19 New York University Treatment methods using atoxic neurotoxin derivatives
AU2014240116B2 (en) * 2013-03-15 2016-12-15 The Trustees Of The University Of Pennsylvania Mono or multivalent botulinum neurotoxin based vaccine using the heavy chain from serotypes of Clostridium botulinum
WO2015132004A1 (en) 2014-03-05 2015-09-11 Merz Pharma Gmbh & Co. Kgaa Novel recombinant clostridial neurotoxins with increased duration of effect
US11897921B2 (en) 2014-12-09 2024-02-13 New York University Propeptide fusion comprising a mutated clostridium botulinum neurotoxin and a VHH domain
KR102514666B1 (ko) 2014-12-19 2023-03-27 메르츠 파마 게엠베하 운트 코. 카가아 세포에서 BoNT/E의 생물학적 활성의 결정을 위한 수단 및 방법
WO2016110662A1 (en) * 2015-01-09 2016-07-14 Ipsen Bioinnovation Limited Cationic neurotoxins
TW201718627A (zh) 2015-06-11 2017-06-01 梅茲製藥有限兩合公司 重組梭菌神經毒素及其使用與形成方法、包括其之醫藥組合物及對應其之前驅物、編碼前驅物之核酸序列及其獲得方法與前驅物之形成方法、載體與包括核酸序列之重組宿主細胞
US11078472B2 (en) 2016-01-20 2021-08-03 Merz Pharma Gmbh & Co., Kgaa Recombinant clostridial neurotoxins with increased duration of effect
CN108463242A (zh) 2016-03-02 2018-08-28 梅尔兹制药公司 包含肉毒杆菌毒素的组合物
EP3290437A1 (en) 2016-08-31 2018-03-07 Merz Pharma GmbH & Co. KGaA Novel recombinant clostridial neurotoxins with decreased duration of effect
KR102480965B1 (ko) 2016-09-13 2022-12-26 알레간 인코포레이티드 안정화된 비단백질 클로스트리듐 독소 조성물
EP3312193A1 (en) 2016-10-19 2018-04-25 Merz Pharma GmbH & Co. KGaA Novel recombinant botulinum neurotoxins with accelerated onset of effect
EP3333179A1 (en) 2016-12-07 2018-06-13 Merz Pharma GmbH & Co. KGaA Novel recombinant botulinum toxin with accelarated onset of effect
EP3335719A1 (en) 2016-12-14 2018-06-20 Merz Pharma GmbH & Co. KGaA Novel recombinant botulinum neurotoxins with a stabilized light chain
WO2018233813A1 (en) 2017-06-20 2018-12-27 Merz Pharma Gmbh & Co. Kgaa NOVEL RECOMBINANT BOTULINUM TOXINS WITH INCREASED DURATION
EP3649143B1 (en) 2017-07-06 2022-08-31 Merz Pharma GmbH & Co. KGaA Novel recombinant botulinum neurotoxins with increased duration of effect
US20210008156A1 (en) 2017-10-26 2021-01-14 Merz Pharma Gmbh & Co. Kgaa Novel recombinant botulinum neurotoxins with increased duration of effect
US20200354706A1 (en) 2017-11-22 2020-11-12 Merz Pharma Gmbh & Co. Kgaa Novel recombinant botulinum toxin with increased duration of effect
WO2019152380A1 (en) * 2018-01-30 2019-08-08 Children's Medical Center Corporation Production of botulinum neurotoxins using bacillus systems
US11707510B2 (en) * 2018-02-16 2023-07-25 Preclinics Discovery Gmbh Nucleic acid-based botulinum neurotoxin for therapeutic use
EP3931319A1 (en) * 2019-02-28 2022-01-05 ProteoNic Biotechnology IP B.V. Self-immolative plasmid backbone
US20240158773A1 (en) * 2021-03-15 2024-05-16 Children's Medical Center Cprporation Engineered botulinum neurotoxin a protease domain with improved efficacy
GB202104294D0 (en) * 2021-03-26 2021-05-12 Ipsen Biopharm Ltd Clostridial neurotoxins comprising an exogenous activation loop

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2003383A1 (en) * 1988-11-23 1990-05-23 Sushil G. Devare Synthetic dna derived recombinant hiv antigens
UA48104C2 (uk) * 1991-10-04 2002-08-15 Новартіс Аг Фрагмент днк, який містить послідовність,що кодує інсектицидний протеїн, оптимізовану для кукурудзи,фрагмент днк, який забезпечує направлену бажану для серцевини стебла експресію зв'язаного з нею структурного гена в рослині, фрагмент днк, який забезпечує специфічну для пилку експресію зв`язаного з нею структурного гена в рослині, рекомбінантна молекула днк, спосіб одержання оптимізованої для кукурудзи кодуючої послідовності інсектицидного протеїну, спосіб захисту рослин кукурудзи щонайменше від однієї комахи-шкідника
US7214787B1 (en) * 1993-09-21 2007-05-08 United States Of America As Represented By The Secretary Of The Army Recombinant vaccine against botulinum neurotoxin
US7037680B2 (en) * 1993-09-21 2006-05-02 The United States Of America As Represented By The Secretary Of The Army Recombinant light chains of botulinum neurotoxins and light chain fusion proteins for use in research and clinical therapy
NZ295998A (en) * 1994-10-24 1999-10-28 Ophidian Pharm Inc Neutralizing antitoxins against clostridium difficile and clostidium botulinum toxins
US6114148C1 (en) * 1996-09-20 2012-05-01 Gen Hospital Corp High level expression of proteins
US6392022B1 (en) * 1997-07-11 2002-05-21 Chugai Seiyaku Kabushiki Kaisha Gene originating in human chondrocyte
US6277622B1 (en) * 1997-08-11 2001-08-21 The University Of Sydney Synthetic polynucleotides
US6218188B1 (en) * 1997-11-12 2001-04-17 Mycogen Corporation Plant-optimized genes encoding pesticidal toxins
US6214602B1 (en) * 1998-08-28 2001-04-10 Promega Corporation Host cells for expression of clostridial toxins and proteins
AU783450B2 (en) * 1999-05-12 2005-10-27 United States Army Medical Research Materiel Command (Usamrmc) Recombinant vaccine against botulinum neurotoxin
US6399857B1 (en) * 1999-09-22 2002-06-04 Paradigm Genetics, Inc. Modified nucleotide sequence encoding a LexA DNA binding domain optimized for arabidopsis species
AU2002211490A1 (en) * 2000-10-04 2002-04-15 The Trustees Of The University Of Pennsylvania Compositions and methods of using capsid protein from flaviviruses and pestiviruses
AU2003249208B2 (en) * 2002-07-16 2010-03-04 Vgx Pharmaceuticals, Llc Codon optimized synthetic plasmids
US20080057575A1 (en) * 2004-08-04 2008-03-06 Allergan, Inc. Optimizing Expression of Active Botulinum Toxin Type A

Similar Documents

Publication Publication Date Title
JP2008508886A5 (cg-RX-API-DMAC7.html)
Shi et al. The low molecular mass subunits of the photosynthetic supracomplex, photosystem II
Pfeifer Distribution, formation and regulation of gas vesicles
JP2009148257A5 (cg-RX-API-DMAC7.html)
Manzoor et al. Genome-guided analysis and whole transcriptome profiling of the mesophilic syntrophic acetate oxidising bacterium Syntrophaceticus schinkii
JP2010279377A5 (cg-RX-API-DMAC7.html)
EA200900512A1 (ru) Метаболическая инженерия сбраживающих арабинозу дрожжевых клеток
WO2005069762A8 (en) Bacillus licheniformis chromosome
JP2011097941A5 (cg-RX-API-DMAC7.html)
ATE512980T1 (de) Polypeptide mit beta-glucosidase-aktivität sowie diese codierende polynukleotide
JP2011516063A5 (cg-RX-API-DMAC7.html)
JP2009502127A5 (cg-RX-API-DMAC7.html)
JP2017532039A5 (cg-RX-API-DMAC7.html)
Reznicek et al. Improved xylose uptake in Saccharomyces cerevisiae due to directed evolution of galactose permease Gal2 for sugar co‐consumption
HUE031212T2 (en) Preparation of isobutanol by fermentation with yeast
JP2006526394A5 (cg-RX-API-DMAC7.html)
JP2007175057A5 (cg-RX-API-DMAC7.html)
EP4449858A3 (en) Compositions and methods for enhancing resistance to northern leaf blight in maize
JP2010501167A5 (cg-RX-API-DMAC7.html)
WO2007118790A3 (en) Active potassium channel transporters (akt) and their use to create stress tolerant plants
JP2010530223A5 (cg-RX-API-DMAC7.html)
JP2005532815A5 (cg-RX-API-DMAC7.html)
WO2008041863A8 (en) Novel genes and polypeptides associated with insecticidal activity
WO2009058030A3 (en) Resistance gene and uses thereof
JP2011527367A5 (cg-RX-API-DMAC7.html)